Challenges of treatment of patients with acute coronary syndrome undergoing hemodialysis

Authors: Tavlueva E.V. 1 2, Shilov A.A. 2, Barbarash O.L. 1

Company: 1 Research Institute for Complex Issues of Cardiovascular Diseases, Sosnovyy bul’var, 6, Kemerovo, 650002, Russian Federation;
2 Kemerovo Regional Clinical Cardiology Dispensary named after academician L.S. Barbarash, Sosnovyy bul’var, 6, Kemerovo, 650002, Russian Federation

For correspondence:  Sign in or register.

Type:  Case reports


DOI: https://doi.org/10.24022/1997-3187-2017-11-2-159-168

For citation: Tavlueva E.V., Shilov A.A., Barbarash O.L. Challenges of treatment of patients with acute coronary syndrome undergoing hemodialysis. Kreativnaya kardiologiya (Creative Cardiology, Russian journal). 2017; 11 (2): 159—68 (in Russ.). DOI: http://dx.doi.org/10.24022/1997-3187-2017-11-2-159-168

Received / Accepted:  May 22, 2017 / May 31, 2017

Keywords: acute coronary syndrome hemodialysis

Download
Full text:  

 

Abstract

This article presents a case report of the patient with acute coronary syndrome, undergoing hemodialysis for 15 years. Approaches to the problems of the revascularization and medical support in these patients are discussed.

References

  1. Sud M., Naimark D.M.J. Cardiovascular disease in chronic kidney disease in 2015. Curr. Op. Nephrol. Hypertens. 2016; 25: 203—7.

  2. Barbarash O.L., Zykov M.V., Bykova I.S., Kashtalap V.V., Karetni-kova V.N., Barbarash L.S. Role of renal dysfunction and multifocal atherosclerosis in the assessment of prognosis in patients with myocardial infarction and ST-segment elevation. Kardiologiya (Cardiology, Russian journal). 2013; 9: 26—32 (in Russ.).

  3. Migliori M., Cantaluppi V., Scatena A., Panichi V. Antiplatelet agents in hemodialysis. J. Nephrol. 2017; 30 (3): 373—83. https://link.springer.com/ article/10.1007/s40620-016-0367-5 (дата обращения/accessed 08.12.2016).

  4. Churchill D.N., Taylor D.W, Cook R.J. Canadian hemodialysis morbidity study. Am. J. Kidney Dis. 1992; 19: 214-34.

  5. Webster A.C., Nagler E.V., Morton R.L., Masson P Chronic kidney disease. Lancet. 2016; 389 (10075): 1238-52. http://www.thelancet.com/journals/ lancet/article/PIIS0140-6736(16)32064-5/fulltext (дата обращения/accessed 22.11.2016).

  6. Windecker S., Kolh P, Alfonso F., Collet J.P, Cremer J., Falk V. et al. 2014 ASC/EACTS Guidelines on myocardial revascularization. The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2014; 35: 2541-619.

  7. Bangalore S., Guo Y, Samadashvili Z., Blecker S., Xu J., Hannan E.L. Revascularization in patients with multivessel coronary artery disease and chronic kidney diseas. J. Am. Coll. Cardiol. 2015; 66 (11): 1209-20.

  8. Shroff G.R., Solid C.A., Herzog C.A. Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States. Circulation. 2013; 127: 1861-9.

  9. Marui A., Kimura T, Nishiwaki N., Mitsudo, K., 18. Komiya, T, Hanyu, M. et al. For the CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with end-stage renal disease requiring dialysis (5-year outcomes of the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am. J. Cardiol. 2014; 114: 555-61. 19.

  10. Roberts J.K., McCullough PA. The Management of acute coronary syndromes in patients with chronic kidney disease. Adv. Chronic Kidney Dis. 2014; 21: 472-9.

  11. Weir M.A., Dixon S.N., Fleet J.L., Roberts M.A., Hackam D.G., Oliver M.J. et al. p-Blocker dialyz-ability and mortality in older patients receiving hemodialysis. JASN. 2015; 26: 987-96.

  12. Shroff G.R., Herzog C.A. p-Blockers in dialysis 20 patients: a nephrocardiology perspective. J. Am. Soc. Nephrol. 2015; 26 (4): 774-6.

  13. Jeong K.H., Cho J.H., Woo J.S., Kim J.B., Kim WS., Lee T.W. et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. Am. J. Kidney Dis. 2015; 65 (6): 916-24.

  14. Vazquez E., Sanchez-Perales C., Ortega S., Vazquez-Sanchez T, Quesada E., Salas D. et al. Bleeding risk of anti-thrombotic treatment in 21 patients on haemodialysis. J. Cardiovasc. Pharmacol. 2017; 69 (4): 192-7.

  15. Summaria F., Giannico M.B., Talarico G.P. Patrizi R. Antiplatelet therapy in hemodialysis 22 patients undergoing percutaneous coronary interventions. Nephrourol. Mon. 2015; 7 (4): e28099.

  16. Hiremath H., Holden R.M., Fergusson D., Zimmerman D.L. Antiplatelet medications in hemodialysis patients: a systematic review of bleed- 23 ing rates. CJASN. 2009; 4 (8): 1347-55.

  17. Moradi H., Streja E., Kashyap M.L., Vaziri N.D., Fonarow G.C., Kalantar-Zadeh K. Elevated high- 24 density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrol. Dial. Transplant. 2014; 29 (8): 1554-62.

  18. Barylski M., Nikfar S., Mikhailidis D.P, Toth P.P., Salari P, Ray K.K. et al. Lipid and blood pressure meta-analysis collaboration group. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy - a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol. Res. 2013; 72: 35-44.

  19. Drapkina O.M., Korneeva O.N. Statins in chronic kidney disease. Is there a variety of drugs? Kardiovasku-lyarnaya Terapiya i Profilaktika (Cardiovascular Therapy and Prevention, Russian journal). 2015; 14 (6): 78-82 (in Russ.).

  20. Sarafidis PA., Persu A., Agarwal R., Burnier M., de Leeuw P., Ferro C. et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). Nephrol. Dial. Transplant. 2017; 32 (4): 620-40.

  21. KDIGO Panel. KDIGO clinical practice guide -line for the management of blood pressure in chronic kidney disease. Kidney Int. Suppl. 2012; 2: 343-87.

  22. Perkovic V., Li X., Xie X., Liu Y. Renin-angio-tensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A Bayesian network meta-analysis of randomized clinical trials. AJKD. 2016; 67: 728-41.

  23. Georgianos PI., Agarwal R. Pharmacotherapy of hypertension in chronic dialysis patients. Clin. J. Am. Soc. Nephrol. 2016; 11 (11): 2062-75.

  24. Bakris G.L., Burkart J.M., Weinhandl E.D. Intensive hemodialysis, blood pressure, and antihypertensive medication use. Am. J. Kidney Dis. 2016; 68 (5, Suppl. 1): S15-23.

About Authors

  • Tavlueva Evgeniya Valer’evna, ORCID, Dr Med. Sc., Leading Researcher, Head of Department;
  • Shilov Aleksandr Aleksandrovich, ORCID, Cand. Med. Sc., Head of Department;
  • Barbarash Ol’ga Leonidovna, ORCID, Corresponding Member of Russian Academy of Sciences, Professor, Dr Med. Sc., Director

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery